When Elizabeth Holmes went to court last year to face 11 charges of defrauding investors and patients through her disgraced biotech company Theranos, it looked like Silicon Valley itself was on trial. If the court came down hard on her, it could end the “fake it till you make it” mantra that seeded so many successful tech firms.

Her $9bn (R143bn) valuation was achieved by pitching a product that was alluring in theory but didn’t work in practice (and quite possibly never would)...

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.